FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297002> ?p ?o ?g. }

• W4286297002 endingPage "e21117" @default.
• W4286297002 startingPage "e21117" @default.
• W4286297002 abstract "e21117 Background: Fusions in the ROS1 proto-oncogene are among the best treatable genetic aberrations in Non-small cell lung cancer (NSCLC). Besides the occurrence of solvent-front mutations (SFM) in acquired resistance to targeted therapy, little is known about ROS1 aberrations other than fusions. We analyzed molecular and clinical characteristics and metastatic patterns of ROS1 mutations in NSCLC patients without activating ROS1 fusions or SFMs. Methods: Next-generation sequencing (NGS) was performed on tissue samples from NSCLC patients within the National Network Genomic Medicine (nNGM). Patients with activating ROS1 fusions detected by fluorescence in-situ hybridization (FISH) were excluded. Staging and restaging procedures were performed following local standards from each partner. We analyzed the mutations’ characteristics, co-occurring mutations and metastatic patterns. Results: Of 8072 patients analyzed by NGS between 2018 and 2021, 118 (1.5%) patients harbored ROS1 mutations. Most patients were male (76.3%) and had adenocarcinoma histology (57.6%). The median age at diagnosis amounted to 68 years. Nearly all of the patients (96.5%) had a smoking history, amassing 40 pack-years on average. Besides TP53 mutations (61.0%), KRAS (25.4%), EGFR (7.6%), PIK3CA and FGFR1-4 mutations (5.9% each) co-occurred most frequently. In 12 (10.2%) patients, ROS1 mutation was the only detected aberration. The majority (59.3%) of patients had UICC stage IV whereby 27.2% of patients featured Stage III; about 7% fall upon stage I and II. The metastatic pattern of all stage IV patients shows that 22.9% of metastasis is allotted to cerebral, 12.5% to lung, 16.7% to subdiaphragmatic, 14.9% to bone and 6.3% to skin metastasis. Thereby, the patients’ subgroup with mutually exclusive ROS1 mutations (10.2%) resembles this trend: about a half of these patients had UICC stage IV, too, and the metastasis distribution featured similar characteristics. Conclusions: The cohort contrasts the clinical characteristics of patients with ROS1 fusion regarding sex, age, and histology. This evidence implies a basic clinical impact exerted by this molecular subtype. We warrant further research on the detected mutations to characterize the biological impact and the potential to act as a drug target." @default.
• W4286297002 created "2022-07-21" @default.
• W4286297002 creator A5001163737 @default.
• W4286297002 creator A5004869064 @default.
• W4286297002 creator A5006555690 @default.
• W4286297002 creator A5006712577 @default.
• W4286297002 creator A5008696832 @default.
• W4286297002 creator A5009342385 @default.
• W4286297002 creator A5017328208 @default.
• W4286297002 creator A5029868866 @default.
• W4286297002 creator A5037915780 @default.
• W4286297002 creator A5045041556 @default.
• W4286297002 creator A5047435894 @default.
• W4286297002 creator A5056803492 @default.
• W4286297002 creator A5063450639 @default.
• W4286297002 creator A5063777522 @default.
• W4286297002 creator A5068843113 @default.
• W4286297002 creator A5080059818 @default.
• W4286297002 creator A5087050668 @default.
• W4286297002 creator A5087282507 @default.
• W4286297002 creator A5090561061 @default.
• W4286297002 creator A5091178170 @default.
• W4286297002 date "2022-06-01" @default.
• W4286297002 modified "2023-10-15" @default.
• W4286297002 title "Metastatic patterns plus clinical and molecular characteristics of <i>ROS1</i> aberrations in non-small cell lung cancer patients without rearrangements." @default.
• W4286297002 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e21117" @default.
• W4286297002 hasPublicationYear "2022" @default.
• W4286297002 type Work @default.
• W4286297002 citedByCount "0" @default.
• W4286297002 crossrefType "journal-article" @default.
• W4286297002 hasAuthorship W4286297002A5001163737 @default.
• W4286297002 hasAuthorship W4286297002A5004869064 @default.
• W4286297002 hasAuthorship W4286297002A5006555690 @default.
• W4286297002 hasAuthorship W4286297002A5006712577 @default.
• W4286297002 hasAuthorship W4286297002A5008696832 @default.
• W4286297002 hasAuthorship W4286297002A5009342385 @default.
• W4286297002 hasAuthorship W4286297002A5017328208 @default.
• W4286297002 hasAuthorship W4286297002A5029868866 @default.
• W4286297002 hasAuthorship W4286297002A5037915780 @default.
• W4286297002 hasAuthorship W4286297002A5045041556 @default.
• W4286297002 hasAuthorship W4286297002A5047435894 @default.
• W4286297002 hasAuthorship W4286297002A5056803492 @default.
• W4286297002 hasAuthorship W4286297002A5063450639 @default.
• W4286297002 hasAuthorship W4286297002A5063777522 @default.
• W4286297002 hasAuthorship W4286297002A5068843113 @default.
• W4286297002 hasAuthorship W4286297002A5080059818 @default.
• W4286297002 hasAuthorship W4286297002A5087050668 @default.
• W4286297002 hasAuthorship W4286297002A5087282507 @default.
• W4286297002 hasAuthorship W4286297002A5090561061 @default.
• W4286297002 hasAuthorship W4286297002A5091178170 @default.
• W4286297002 hasConcept C104317684 @default.
• W4286297002 hasConcept C121608353 @default.
• W4286297002 hasConcept C126322002 @default.
• W4286297002 hasConcept C142724271 @default.
• W4286297002 hasConcept C143998085 @default.
• W4286297002 hasConcept C146357865 @default.
• W4286297002 hasConcept C151730666 @default.
• W4286297002 hasConcept C2775999482 @default.
• W4286297002 hasConcept C2776256026 @default.
• W4286297002 hasConcept C2777542201 @default.
• W4286297002 hasConcept C2779013556 @default.
• W4286297002 hasConcept C2781182431 @default.
• W4286297002 hasConcept C2781187634 @default.
• W4286297002 hasConcept C30481170 @default.
• W4286297002 hasConcept C501734568 @default.
• W4286297002 hasConcept C502942594 @default.
• W4286297002 hasConcept C526805850 @default.
• W4286297002 hasConcept C54355233 @default.
• W4286297002 hasConcept C71924100 @default.
• W4286297002 hasConcept C86803240 @default.
• W4286297002 hasConceptScore W4286297002C104317684 @default.
• W4286297002 hasConceptScore W4286297002C121608353 @default.
• W4286297002 hasConceptScore W4286297002C126322002 @default.
• W4286297002 hasConceptScore W4286297002C142724271 @default.
• W4286297002 hasConceptScore W4286297002C143998085 @default.
• W4286297002 hasConceptScore W4286297002C146357865 @default.
• W4286297002 hasConceptScore W4286297002C151730666 @default.
• W4286297002 hasConceptScore W4286297002C2775999482 @default.
• W4286297002 hasConceptScore W4286297002C2776256026 @default.
• W4286297002 hasConceptScore W4286297002C2777542201 @default.
• W4286297002 hasConceptScore W4286297002C2779013556 @default.
• W4286297002 hasConceptScore W4286297002C2781182431 @default.
• W4286297002 hasConceptScore W4286297002C2781187634 @default.
• W4286297002 hasConceptScore W4286297002C30481170 @default.
• W4286297002 hasConceptScore W4286297002C501734568 @default.
• W4286297002 hasConceptScore W4286297002C502942594 @default.
• W4286297002 hasConceptScore W4286297002C526805850 @default.
• W4286297002 hasConceptScore W4286297002C54355233 @default.
• W4286297002 hasConceptScore W4286297002C71924100 @default.
• W4286297002 hasConceptScore W4286297002C86803240 @default.
• W4286297002 hasIssue "16_suppl" @default.
• W4286297002 hasLocation W42862970021 @default.
• W4286297002 hasOpenAccess W4286297002 @default.
• W4286297002 hasPrimaryLocation W42862970021 @default.
• W4286297002 hasRelatedWork W1964917847 @default.
• W4286297002 hasRelatedWork W1983690566 @default.
• W4286297002 hasRelatedWork W2005841680 @default.
• W4286297002 hasRelatedWork W2066758858 @default.

• next